Synthesis and characterization of a hemoglobin-ribavirin conjugate for targeted drug delivery

Bioconjugate Chemistry

Volumn 17, Issue 2, 2006, Pages 530-537

  Brookes, Steve ^a   Biessels, Pieter ^a   Ng, Nancy F L ^a   Woods, Caroline ^a   Bell, David N ^a   Adamson, Gord ^a  

^a Hemosol Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCOMPATIBILITY; CELL CULTURE; CONTROLLED DRUG DELIVERY; DISEASES; DRUG INTERACTIONS; HEMOGLOBIN; MOLECULAR BIOLOGY; TARGETED DRUG DELIVERY;

DRUG CARRIER; HAEMOGLOBINS; HEPATITIS C; LIVER DISEASE; NUCLEOSIDE ANALOGS; RIBAVIRIN; SIDE EFFECT; SYNTHESIS AND CHARACTERIZATIONS; SYNTHESISED; TARGETED DELIVERY;

AMIDES;

5' MONOPHOSPHORIMIDAZOLIDE; ACID PHOSPHATASE; CARBOXYHEMOGLOBIN; CD163 ANTIGEN; DRUG CARRIER; HAPTOGLOBIN; HEMOGLOBIN; HYDROXYL GROUP; IMIDAZOLE DERIVATIVE; INTERFERON; PHOSPHATE; PHOSPHORAMIDIC ACID DERIVATIVE; RIBAVIRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG METABOLISM; DRUG SYNTHESIS; ELECTROSPRAY MASS SPECTROMETRY; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER DISEASE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALIA; HEPATITIS C VIRUS;

EID: 33645228635     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0503317     Document Type: Article

References (55)

1. Francis, G. E., and Delgado, C. (2000) Drug targeting. Strategies, principles, and applications. Humana Press, Inc., Totowa, NJ.
2. Rihova, B. (1998) Receptor-mediated targeted drug or toxin delivery. Adv. Drug Delivery Rev. 29, 273-289.
3. Moghimi, S. M., and Rajabi-Siahboomi, A. R. (2000) Recent advances in cellular, sub-cellular and molecular targeting. Adv. Drug Delivery Rev. 41, 129-133.
4. Goyal, P., Goyal, K., Vijaya Kumar, S. G., Singh, A., Katare, O. P., and Mishra, D. N. (2005) Liposomal drug delivery systems-clinical applications. Acta Pharm. 55, 1-25.
5. Ambade, A. V., Savariar, E. N., and Thayumanavan, S. (2005) Dendrimeric micelles for controlled drug release and targeted delivery. Mol. Pharm. 2, 264-272.
6. Uekama, K. (2004) Design and evaluation of cyclodextrin-based drug formulation. Chem. Pharm. Bull. (Tokyo) 52, 900-915.
7. Perutz, M. F. (1978) Hemoglobin structure and respiratory transport. Sci. Am. 239, 92-125.
8. Shaeffer, J. R., McDonald, M. J., Turci, S. M., Dinda, D. M., and Bunn, H. F. (1984) Dimer-monomer dissociation of human hemoglobin A. J. Biol. Chem. 259, 14544-14547.
9. Nagel, R. L., and Gibson, Q. H. (1971) The binding of hemoglobin to haptoglobin and its relation to subunit dissociation of hemoglobin. J. Biol. Chem. 246, 69-73.
10. Javid, J. (1978) Human haptoglobins. Curr. Top. Hematol. 1, 151-192.
11. Dobryszycka, W. (1997) Biological functions of haptoglobin-new pieces to an old puzzle. Eur. J. Clin. Chem. Clin. Biochem. 35 (9), 647-654.
12. Nagel, R. L., and Gibson, Q. H. (1967) Kinetics and mechanism of complex formation between hemoglobin and haptoglobin. J. Biol. Chem. 242 (15), 3428-3434.
13. Keene, W. R., and Jandl, J. H. (1965) The sites of hemoglobin catabolism. Blood 26, 705-719.
14. Hershko, C., Cook, J. D., and Finch, C. A. (1972) Storage iron kinetics. II. The uptake of Hb iron by hepatic parenchymal cells. J. Lab. Clin. Med. 80, 624.
15. Ship, N. J., Toprak, A., Lai, R. P., Tseng, E., Kluger, R., and Pang, K. S. (2005) Binding of acellular, native and cross-linked human hemoglobins to haptoglobin: enhanced distribution and clearance in the rat. Am. J. Physiol.: Gastrointest. Liver Physiol. 288, G1301-G1309.
16. Okuda, M., Tokunaga, R., and Taketani, S. (1992) Expression of haptoglobin receptors in human hepatoma cells. Biochim. Biophys. Acta 1136, 143-9.
17. Zuwala-Jagiello, J., and Osada, J. (1998) Internalization study using EDTA-prepared hepatocytes for receptor-mediated endocytosis of haemoglobin-haptoglobin complex. Int. J. Biochem. Cell Biol. 30, 923-31.
18. Kristiansen, M., Graversen, J. H., Jacobsen, C., Sonne, O. Hoffman, H. J., Law, S. K. A., and Moestrup, S. K. (2001) Identification of the haemoglobin scavenger receptor. Nature 409, 198-201.
19. Hiraoka, A., Horiike, N., Akbar, S. M. F., Michitaka, K., Matsuyama, T., and Onji, M. (2005) Expression of CD163 in the liver of patients with viral hepatitis. Pathol., Res. Pract. 201, 379-384.
20. Schaer, D. J., Boretti, F., S., Hongegger, A., Poehler, D., Linnscheid, P., Staege, H., Muller, C., Schoedon, G., and Schaffner, A. (2001) Molecular cloning and characterization of the mouse CD163 homologue, a highly glucocorticoid-inducible member of the scavenger receptor cysteine-rich family. Immunogenetics 53, 170-177.
21. Moestrup, S. K., and Moller, H. J. (2004) CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response. Ann. Med. 36, 347-354.
22. Weinstein, M. B., and Segal, H. L. (1984) Uptake of free hemoglobin by rat liver parenchynmal cells. Biochem. Biophys. Res. Commun. 123, 489-496.
23. Scherphof, G. L., Koning, G., Bartsch, M., Yan, X., and Kamps, J. (2002) Targeting liposomes and lipoplexes to cells in the liver. Cell. Mol. Biol. Lett. 7, 251-254.
24. Lauer, G., and Walker, B. D. (2001) Hepatitis C virus infection. N. Engl. J. Med. 345, 41-52.
25. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiftman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., Albrecht, J. K., and the International Hepatitis Interventional Therapy Group. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358, 958-965.
26. Takaki, S., Tsubota, A., Hosaka, T., Akuta, N., Someya, T., Kobayashi, M., Suzuki, F., Suzuki, Y., Saitoh, S., Arase, Y., Ikeda, K., and Kumada, H. (2004) Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J. Gastroenterol. 39, 668-673.
27. Lau, J. N. J., Tam, R. C., Liang, T. J., and Hong, Z. (2002) Mechanism of action of ribavirin in combination treatment of chronic HCV infection. Hepatology 35, 1002-1009.
28. Di Stefano, G., Bignamini, A., Busi, C., Colonna, F. P., and Fiume, L. (1997) Enhanced accumulation of ribavirin and its metabolites in liver versus erythrocytes in mice administered with the liver targeted drug. Ital. J. Gastroenterol. Hepatol. 29, 420-426.
29. Fiume, L., Di Stefano, G., Busi, C., Incitti, P., Rapicetta, M., Farina, C., Gervasi, G. B., and Bonino, F. (1998) Coupling to lactosaminated poly-L-lysine reduces the toxic effects of ribavirin on red blood cells. J. Hepatol. 29, 1032-1033.
30. 31P NMR signals: II. Study of conjugates of ara-AMP with lactosaminated albumin. Phys. Med. Biol. 37, 1-12.
31. Fiume, L., Busi, G. Di Stefano, G., and Mattioli, A. (1993). Coupling of antiviral nucleoside analogues to lactosaminated human albumin by using the imidazolides of their phosphoric esters. Anal. Biochem. 212, 407-411.
32. Pliura, D., Wiffen, D., Ashraf, S., and Magnin, A. (1995) Displacement chromatography process. United States Patent 5,439,591.
33. Jones, R. T. (1994) Structural characterization of modified hemoglobins. Methods Enzymol. 231, 322-343.
34. Allen, L. B., Boswell, K. H., Khwaja, T. A., Meyer, R. R., Sidwell, R. W., and Witkowski, J. T. (1978) Synthesis and antiviral activity of some phosphates of the broad-spectrum antiviral nucleosides, 1-β-D- ribofuranosyl-1,2,4-triazole-3-carboxamide (Ribavirin). J. Med. Chem. 21, 742-746.
35. Ames, B. (1966) Assay of inorganic phosphate, total phosphate and phosphatases. In Methods in Enzymology (Neufeld, E., and Ginsburg, V., Eds.) Vol. 8, pp 115-118, Academic Press, New York/ London.
36. Streeter, D. G., Witkowski, J. T., Khare, G. P., Sidwell, R. W., Bauer, R. J., Robins, R. K., and Simon, L. N. (1973) Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole), a new broad spectrum antiviral agent. Proc. Natl. Acad. Sci. 70, 1174-1178.
37. Schaer, D. J., Boretti, F. S., Schoedon, G., and Schaffner, A. (2002) Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel anti-inflammatory action of glucocorticoids. Br. J. Haematol. 119, 239-243.
38. Tam, R. C., Lau, J. Y., and Hong, Z. (2001) Mechanisms of action of ribavirin in antiviral therapies. Antivir. Chem. Chemother. 12, 261-272.
39. Baddiley, J., Buchanan, J. G., and Letters, R. (1956) Phosphorylation through glyoxalines (imidazoles) and its significance in enzymic transphosphorylation. J. Chem. Soc., 2812-2817.
40. Staab, H. A., Scaller, H., and Cramer, F. (1959) An imidazolide of phosphoric acid. Angew. Chem. 71, 736.
41. Manning, J. M. (1994) Methods Enzymol. 231, 225-246.
42. Lim, S.-K., Ferraro, B., Moore, K., and Halliwell, B. (2001) Role of haptoglobin in free hemoglobin metabolism. Redox Report 6, 219-227.
43. Adamson, J. G., Wodzinska, J. M., and Moore, M. S. C. (2002) Hemoglobin-haptoglobin complexes. United States Patent 6,479,637.
44. Benesch, R. E., Ikeda, S., and Benesch, R. (1976) Reaction of haptoglobin with hemoglobin covalently cross-linked between the alpha beta dimers. J. Biol. Chem. 251, 465-470.
45. Panter, S. S., Vandegriff, K. D., Yan, P. O., and Regan, R. F. (1994) Assessment of hemoglobin-dependent neurotoxicity: alpha-alpha cross-linked hemoglobin. Artif. Cells, Blood Substitutes, Immobilization Biotechnol. 22, 399-413.
46. Baker, S., and Dodds, S. (1925) Obstruction of the renal tubules during the excretion of hemoglobin. Br. J. Exp. Pathol. 6, 247-260.
47. Lieberthal, W. (1997) Renal effects of hemoglobin-based blood substitutes. In Red cell substitutes: basic principles and clinical application (Rudolph, A. S., Feuerstein, G., and Rabinovici, R., Eds.) pp 189-217, Marcell Dekker, New York.
48. Nguyen, T. T., Schwartz, E. J., West, R. B., Warnke, R. A., Arber, D. A., and Natkunam, Y. (2005) Expression of CD163 (hemoglobin scavenger receptor) in normal tissues, lymphomas, carcinomas, and sarcomas is largely restricted to the monocyte/macrophage lineage. Am. J. Surg. Pathol. 29 (5), 617-624.
49. Limet, J. N., Quintart, J., Otte-Slachmuylder, C., and Schneider, Y. J. (1982) Receptor mediated endocytosis of hemoglobin-haptoglobin, galactosylated serum albumin and polymeric IgA by the liver. Acta Biol. Med. Ger. 41, 113-124.
50. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th ed. (Gilman, A. G., Ed.), McGraw-Hill, Inc., Toronto, 1996.
51. Crotty, S., Cameron, C. E., and Andino, R. (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc. Natl. Acad. Sci. U.S.A. 98, 6895-6900.
52. Page, T., and Connor, J. D. (1990) The metabolism of ribavirin in erythrocytes and nucleated cells. Int. J. Biochem. 22, 379-383.
53. Levy, G., Adamson, G., Phillips, M. J., Scrocchi, L., Fung, L., Biessels, P., Ng, N. F., Ghanekar, A., Rowe, A., Ma, M. X., Levy, A., Koscik, C., He, W., Gorczynski, R., Brookes, S., Woods, C., McGilvray, I. D., and Bell, D. (2005) Targeted delivery of ribavirin improves outcome to murine hepatitis virus induced fulminant hepatitis through enhanced anti-viral activity. Hepatology (submitted manuscript).
54. Glue, P. (1999) The clinical pharmacology of ribavirin. Semin. Liver Dis. 19 (Suppl. 1), 17-24.
55. Nakao, M., Nakao, T., and Yamazoe, S. (1960) Adenosine triphosphate and maintenance of shape of the human red cells. Nature 187, 945-946.